Updates on medical treatment for neuroendocrine neoplasm

LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie

doi:10.19401/j.cnki.1007-3639.2022.09.001

Zhongguo aizheng zazhi (Sep 2022)

Updates on medical treatment for neuroendocrine neoplasm

LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie

Affiliations

LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie: 1. Center for Neuroendocrine Tumors, Department of Head, Neck and Neuroendocrine Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;2. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Pancreatic Cancer Institute, Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai 200032, China

DOI: https://doi.org/10.19401/j.cnki.1007-3639.2022.09.001
Journal volume & issue: Vol. 32, no. 9
pp. 757 – 764

Abstract

Read online

Neuroendocrine neoplasm (NEN) is a group of heterogeneous malignancies arising from neuroendocrine cells and peptidergic neurons. According to its cell differentiation, NEN can be divided into two distinct groups as well-differentiated neuroendocrine tumor (NET) and poorly-differentiated neuroendocrine carcinoma (NEC). For advanced NEN, medication is the preferred treatment. In this article, we reviewed current clinical trials in medical treatment for NEN and aimed to provide treatment reference in clinical practice.

|neuroendocrine neoplasms|medicine|clinical trial

Published in Zhongguo aizheng zazhi

ISSN: 1007-3639 (Print)
Publisher: Editorial Office of China Oncology
Country of publisher: China
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.china-oncology.com/EN/1007-3639/home.shtml

About the journal

Abstract

Keywords